CAR-T

Exciting advances in CAR-T and TCR research

Exciting advances in CAR-T and TCR research

David Gilham • 22 Feb 2021

DARIC33 CAR T-cells in AML

DARIC33 CAR T-cells in AML

Jacob Appelbaum • 12 May 2021

Identifying early predictors of neurotoxicity following CAR-T infusion

Identifying early predictors of neurotoxicity following CAR-T infusion

Jaap Boelens • 26 May 2021

Allogenic NKX101 in r/r AML

Allogenic NKX101 in r/r AML

James Trager • 22 Feb 2021

Horizon scanning in anti-CD19 CAR T-cell therapy

Horizon scanning in anti-CD19 CAR T-cell therapy

Marco Alessandrini • 20 May 2021

DARIC33: CAR T with an on/off switch

DARIC33: CAR T with an on/off switch

Jacob Appelbaum • 12 May 2021

What to expect at ISCT 2021

What to expect at ISCT 2021

Bruce Levine • 11 Mar 2021

Combining iNKT and CAR technology

Combining iNKT and CAR technology

Marc van Dijk • 23 Feb 2021

How the TCR field can learn from CARs

How the TCR field can learn from CARs

Dolores Schendel • 25 Feb 2021

Targetting cancer with allogeneic NK cell therapies

Targetting cancer with allogeneic NK cell therapies

James Trager • 10 Mar 2021

CAR-NKs for B cell malignancies

CAR-NKs for B cell malignancies

James Trager • 10 Mar 2021

CT053, anti-GPC3 CAR-T and targeting solid tumors

CT053, anti-GPC3 CAR-T and targeting solid tumors

Hong Ma • 19 Feb 2021

CYAD-101 & alloSHRINK: allogeneic CAR-T cell therapy in MSS mCRC

CYAD-101 & alloSHRINK: allogeneic CAR-T cell therapy in MSS mCRC

David Gilham • 22 Feb 2021

Analysing trends in the CAR-TCR landscape

Analysing trends in the CAR-TCR landscape

Vasiliki Zochiou • 22 Feb 2021

CYCLE-1: next generation NKG2D-based CAR T-cells in AML/MDS

CYCLE-1: next generation NKG2D-based CAR T-cells in AML/MDS

David Gilham • 22 Feb 2021

CAR-TCR Europe highlights: synthetic biology & the autologous vs allogeneic debate

CAR-TCR Europe highlights: synthetic biology & the autologous vs allogeneic debate

Dalip Sethi • 23 Feb 2021

1
2
3
4
5
6
Next